ALDR
Alder BioPharmaceuticals Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-05-2018 after market close | 08-07-2018 after market close | 05-08-2018 after market close | 02-26-2018 after market close | 11-07-2017 after market close | 08-08-2017 after market close | 04-27-2017 after market close | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.91 | -1.04 | -1.73 | -0.8 | -0.92 | -1.48 | -1.99 |
| Consensus EPS | -1.13 | -1.14 | -1.26 | -1.08 | -1.21 | -1.67 | -0.95 |
| Estimated EPS | -1.13 | -1.14 | -1.26 | -1.08 | -1.21 | -1.67 | -0.95 |
| Number of Estimates | 5 | 4 | 4 | 4 | 4 | 5 | 5 |
| EPS Surprise | $0.22 | $0.10 | -$0.47 | $0.28 | $0.29 | $0.19 | -$1.04 |
Stats
Summary
Alder BioPharmaceuticals Inc is a biotechnology company. It is engaged in the discovery, development, and commercialization of therapeutic antibodies addresses diseases with limited medical options. The company operates across the US and Australia.
Market Cap: 1.15 Billion
Primary Exchange: NASDAQ Global Market
Website: http://www.alderbio.com
Shares Outstanding: 67.8 Million
Float: 67.3 Million
Dividend: 0.0 (0.0%)
Beta: 2.861837
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 6.22 Million
Ethical Flags
Longest drawdown: 1001 trading days
From: 2015-06-30 To: 2019-02-20
Lowest Point:
Teva: Reasons To Avoid It In Favor Of Innovative Biotechs
via: SeekingAlpha at 2019-02-19 04:45:10:000
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its … read more...
Teva: Reasons To Avoid It In Favor Of Innovative Biotechs
via: SeekingAlpha at 2019-02-19 04:45:10:000
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its … read more...
Teva: Reasons To Avoid It In Favor Of Innovative Biotechs
via: SeekingAlpha at 2019-02-19 04:45:10:000
Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its … read more...
Short-term budget deal comes just in time for biotech firms
via: CNBC at 2019-01-25 19:05:00:000
No summary available. read more...
Short-term budget deal comes just in time for biotech firms
via: CNBC at 2019-01-25 19:05:00:000
No summary available. read more...
Short-term budget deal comes just in time for biotech firms
via: CNBC at 2019-01-25 19:05:00:000
No summary available. read more...
Short-term budget deal comes just in time for biotech firms
via: CNBC at 2019-01-25 19:05:00:000
No summary available. read more...
Alder Bio a nice bolt-on - Leerink
via: SeekingAlpha at 2019-01-14 10:20:28:000
Alder Biopharmaceuticals ( ALDR +3.6% ) is up on light volume in early trade. Leerink's Geoffrey Porges says the company is an attractive target for a larger outfit looking for a bolt-on acquisition considering its modest $769M market cap. It's a tiny biotech with one main product candid… read more...
Alder Bio a nice bolt-on - Leerink
via: SeekingAlpha at 2019-01-14 10:20:28:000
Alder Biopharmaceuticals ( ALDR +3.6% ) is up on light volume in early trade. Leerink's Geoffrey Porges says the company is an attractive target for a larger outfit looking for a bolt-on acquisition considering its modest $769M market cap. It's a tiny biotech with one main product candid… read more...
Alder Bio a nice bolt-on - Leerink
via: SeekingAlpha at 2019-01-14 10:20:28:000
Alder Biopharmaceuticals ( ALDR +3.6% ) is up on light volume in early trade. Leerink's Geoffrey Porges says the company is an attractive target for a larger outfit looking for a bolt-on acquisition considering its modest $769M market cap. It's a tiny biotech with one main product candid… read more...
Alder Biopharmaceuticals (ALDR) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-01-08 13:36:55:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with this Read more … read more...
Alder Biopharmaceuticals (ALDR) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-01-08 13:36:55:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with this Read more … read more...
Alder Biopharmaceuticals (ALDR) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-01-08 13:36:55:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with this Read more … read more...
Teva up 1% premarket on positive fremanezumab data
via: SeekingAlpha at 2018-12-17 08:38:40:000
Teva Pharmaceutical Industries (NYSE: TEVA ) is up 1% premarket on modest volume in response to its announcement of positive results from a Phase 3 clinical trial, FOCUS , evaluating fremanezumab in adults with chronic or episodic migraine. More news on: Teva Pharmaceutical … read more...
Teva up 1% premarket on positive fremanezumab data
via: SeekingAlpha at 2018-12-17 08:38:40:000
Teva Pharmaceutical Industries (NYSE: TEVA ) is up 1% premarket on modest volume in response to its announcement of positive results from a Phase 3 clinical trial, FOCUS , evaluating fremanezumab in adults with chronic or episodic migraine. More news on: Teva Pharmaceutical … read more...
Teva up 1% premarket on positive fremanezumab data
via: SeekingAlpha at 2018-12-17 08:38:40:000
Teva Pharmaceutical Industries (NYSE: TEVA ) is up 1% premarket on modest volume in response to its announcement of positive results from a Phase 3 clinical trial, FOCUS , evaluating fremanezumab in adults with chronic or episodic migraine. More news on: Teva Pharmaceutical … read more...
Biohaven Pharma up 17% on positive data on migraine med Zydis
via: SeekingAlpha at 2018-12-03 12:05:58:000
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...
Biohaven Pharma up 17% on positive data on migraine med Zydis
via: SeekingAlpha at 2018-12-03 12:05:58:000
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...
Biohaven Pharma up 17% on positive data on migraine med Zydis
via: SeekingAlpha at 2018-12-03 12:05:58:000
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...
Biohaven Pharma up 17% on positive data on migraine med Zydis
via: SeekingAlpha at 2018-12-03 12:05:58:000
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...
Biohaven Pharma up 17% on positive data on migraine med Zydis
via: SeekingAlpha at 2018-12-03 12:05:58:000
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat… read more...
Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space
via: SeekingAlpha at 2018-11-13 16:09:20:000
The Migraine prevention market is estimated to be around $8 billion . Based on the number of migraineurs and the cost per treatment, that might be low. Three new preventative treatments, Lilly's Emgality, Amgen/Novartis Aimovig, and Teva's Ajovy, have been approved in 2018. These are all… read more...
Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space
via: SeekingAlpha at 2018-11-13 16:09:20:000
The Migraine prevention market is estimated to be around $8 billion . Based on the number of migraineurs and the cost per treatment, that might be low. Three new preventative treatments, Lilly's Emgality, Amgen/Novartis Aimovig, and Teva's Ajovy, have been approved in 2018. These are all… read more...
Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space
via: SeekingAlpha at 2018-11-13 16:09:20:000
The Migraine prevention market is estimated to be around $8 billion . Based on the number of migraineurs and the cost per treatment, that might be low. Three new preventative treatments, Lilly's Emgality, Amgen/Novartis Aimovig, and Teva's Ajovy, have been approved in 2018. These are all… read more...
Alder Biopharmaceuticals: Pure Play Migraine Prevention Treatment In A Crowded Space
via: SeekingAlpha at 2018-11-13 16:09:20:000
The Migraine prevention market is estimated to be around $8 billion . Based on the number of migraineurs and the cost per treatment, that might be low. Three new preventative treatments, Lilly's Emgality, Amgen/Novartis Aimovig, and Teva's Ajovy, have been approved in 2018. These are all… read more...
Alder Biopharmaceuticals Inc (ALDR) CEO Robert Azelby on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-06 09:23:08:000
Alder Biopharmaceuticals Inc (ALDR) Q3 2018 Results Earnings Conference Call November 5, 2018 5:00 PM ET Executives Michael Schaffzin - Stern, Investor Relations Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Elisabeth S… read more...
Alder Biopharmaceuticals Inc (ALDR) CEO Robert Azelby on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-06 09:23:08:000
Alder Biopharmaceuticals Inc (ALDR) Q3 2018 Results Earnings Conference Call November 5, 2018 5:00 PM ET Executives Michael Schaffzin - Stern, Investor Relations Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Elisabeth S… read more...
Alder Biopharmaceuticals Inc (ALDR) CEO Robert Azelby on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-06 09:23:08:000
Alder Biopharmaceuticals Inc (ALDR) Q3 2018 Results Earnings Conference Call November 5, 2018 5:00 PM ET Executives Michael Schaffzin - Stern, Investor Relations Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Elisabeth S… read more...
Citi soft on Solid Biosciences in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-06 08:33:42:000
Alder Biopharmaceuticals (NASDAQ: ALDR ) resumed with Outperform rating and $36 (153% upside) price target at Wells Fargo. More news on: Alder Biopharmaceuticals Inc., Solid Biosciences, Inc., AMAG Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the m… read more...
Citi soft on Solid Biosciences in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-06 08:33:42:000
Alder Biopharmaceuticals (NASDAQ: ALDR ) resumed with Outperform rating and $36 (153% upside) price target at Wells Fargo. More news on: Alder Biopharmaceuticals Inc., Solid Biosciences, Inc., AMAG Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the m… read more...
Citi soft on Solid Biosciences in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-06 08:33:42:000
Alder Biopharmaceuticals (NASDAQ: ALDR ) resumed with Outperform rating and $36 (153% upside) price target at Wells Fargo. More news on: Alder Biopharmaceuticals Inc., Solid Biosciences, Inc., AMAG Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the m… read more...
This Stock Reset Requires Patience
via: SeekingAlpha at 2018-10-29 15:53:28:000
Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...
This Stock Reset Requires Patience
via: SeekingAlpha at 2018-10-29 15:53:28:000
Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...
This Stock Reset Requires Patience
via: SeekingAlpha at 2018-10-29 15:53:28:000
Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...
Biotech Stocks Bloodied But Can Now Drive M&A
via: SeekingAlpha at 2018-10-19 12:04:35:000
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...
Biotech Stocks Bloodied But Can Now Drive M&A
via: SeekingAlpha at 2018-10-19 12:04:35:000
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...
Biotech Stocks Bloodied But Can Now Drive M&A
via: SeekingAlpha at 2018-10-19 12:04:35:000
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...
Biotech Stocks Bloodied But Can Now Drive M&A
via: SeekingAlpha at 2018-10-19 12:04:35:000
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...
Biotech Stocks Bloodied But Can Now Drive M&A
via: SeekingAlpha at 2018-10-19 12:04:35:000
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-23 08:21:11:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-23 08:21:11:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-23 08:21:11:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-23 08:21:11:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-23 08:21:11:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...
Alder Biopharmaceuticals Inc's (ALDR) CEO Robert Azelby on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-07 21:42:11:000
Alder Biopharmaceuticals Inc. (ALDR) Q2 2018 Earnings Conference Call August 07, 2018 17:00 P.M. ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Analysts Brian Abraha… read more...
Alder Biopharmaceuticals Inc's (ALDR) CEO Robert Azelby on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-07 21:42:11:000
Alder Biopharmaceuticals Inc. (ALDR) Q2 2018 Earnings Conference Call August 07, 2018 17:00 P.M. ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Analysts Brian Abraha… read more...
Alder Biopharmaceuticals Inc's (ALDR) CEO Robert Azelby on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-07 21:42:11:000
Alder Biopharmaceuticals Inc. (ALDR) Q2 2018 Earnings Conference Call August 07, 2018 17:00 P.M. ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Analysts Brian Abraha… read more...
Alder Biopharmaceuticals Inc's (ALDR) CEO Robert Azelby on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-07 21:42:11:000
Alder Biopharmaceuticals Inc. (ALDR) Q2 2018 Earnings Conference Call August 07, 2018 17:00 P.M. ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Robert Azelby - CEO Eric Carter - Interim CMO Analysts Brian Abraha… read more...
Alder Biopharmaceuticals Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-07 16:48:08:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Alder Bio beats by $0.01
via: SeekingAlpha at 2018-08-07 16:27:13:000
Alder Bio (NASDAQ: ALDR ): Q2 EPS of -$1.04 beats by $0.01 . More news on: Alder Biopharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-06 07:57:30:000
Alder Biopharmaceuticals (NASDAQ: ALDR ) initiated with Overweight rating and $28 (47% upside) price target at Piper Jaffray. More news on: Alder Biopharmaceuticals Inc., Global Blood Therapeutics, Sage Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Teva's pain is Alder's gain in migraine; shares up 15%
via: SeekingAlpha at 2018-06-15 13:16:42:000
Alder Biopharma ( ALDR +14.8% ) is up on almost 40% higher volume as investors believe that Teva's exit from developing CGRP inhibitor fremenezumab for chronic cluster headache is a positive for Alder's CGRP inhibitor eptinezumab, in Phase 3 development for chronic and episodic migraine. … read more...
Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%
via: SeekingAlpha at 2018-06-11 12:25:14:000
As is so often the case, good news for one biotech is bad for another. Allergan ( AGN +1.1% ) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine. More news on: Allergan plc, Alder Biopharmaceuticals Inc., Healthcare stocks… read more...
Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%
via: SeekingAlpha at 2018-06-11 12:25:14:000
As is so often the case, good news for one biotech is bad for another. Allergan ( AGN +1.1% ) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine. More news on: Allergan plc, Alder Biopharmaceuticals Inc., Healthcare stocks… read more...
Allergan's positive data on migraine prevention med atogepant pressures Alder Bio, down 4%
via: SeekingAlpha at 2018-06-11 12:25:14:000
As is so often the case, good news for one biotech is bad for another. Allergan ( AGN +1.1% ) is in the green after reporting positive data on CGRP receptor antagonist atogepant for the prevention of migraine. More news on: Allergan plc, Alder Biopharmaceuticals Inc., Healthcare stocks… read more...
ElectroCore Readies $65 Million U.S. IPO Plans
via: SeekingAlpha at 2018-06-07 14:48:43:000
Quick Take ElectroCore ( ECOR ) intends to raise $65 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is preparing to commercialize a device that promises to treat various forms of headaches. ECOR has a promising, non-invasive treatment op… read more...
ElectroCore Readies $65 Million U.S. IPO Plans
via: SeekingAlpha at 2018-06-07 14:48:43:000
Quick Take ElectroCore ( ECOR ) intends to raise $65 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is preparing to commercialize a device that promises to treat various forms of headaches. ECOR has a promising, non-invasive treatment op… read more...
ElectroCore Readies $65 Million U.S. IPO Plans
via: SeekingAlpha at 2018-06-07 14:48:43:000
Quick Take ElectroCore ( ECOR ) intends to raise $65 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is preparing to commercialize a device that promises to treat various forms of headaches. ECOR has a promising, non-invasive treatment op… read more...
Jounce: Sifting Through The Wreckage
via: SeekingAlpha at 2018-06-04 17:23:37:000
Intro To JTX-2011 The overall theory of the mechanism of action of Jounce's ( JNCE ) JTX-2011 should be easy for investors to understand. Or, at least, here is how I understood it: JTX-2011 is a "dual-role" monoclonal antibody that binds to the ICOS receptor on certain T-cells. In it… read more...
Jounce: Sifting Through The Wreckage
via: SeekingAlpha at 2018-06-04 17:23:37:000
Intro To JTX-2011 The overall theory of the mechanism of action of Jounce's ( JNCE ) JTX-2011 should be easy for investors to understand. Or, at least, here is how I understood it: JTX-2011 is a "dual-role" monoclonal antibody that binds to the ICOS receptor on certain T-cells. In it… read more...
Jounce: Sifting Through The Wreckage
via: SeekingAlpha at 2018-06-04 17:23:37:000
Intro To JTX-2011 The overall theory of the mechanism of action of Jounce's ( JNCE ) JTX-2011 should be easy for investors to understand. Or, at least, here is how I understood it: JTX-2011 is a "dual-role" monoclonal antibody that binds to the ICOS receptor on certain T-cells. In it… read more...
Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?
via: SeekingAlpha at 2018-05-21 04:00:33:000
Recently, it was announced that Amgen ( AMGN ) and its partner Novartis ( NVS ) had received FDA approval for Aimovig for migraine prevention. This a huge first mover advantage in this arena, which should bode well on getting a good lead against competitors. This should be a good push … read more...
Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
via: CNBC at 2018-05-18 17:39:00:000
No summary available. read more...
Amgen's first mover advantage with Aimovig bodes well - analysts
via: SeekingAlpha at 2018-05-18 08:42:33:000
As expected, sell-side analysts are bullish on Amgen (NASDAQ: AMGN ) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S. More news on: Amgen Inc., Allergan plc, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, … read more...
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
via: SeekingAlpha at 2018-05-16 07:38:26:000
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
via: SeekingAlpha at 2018-05-16 07:38:26:000
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
via: SeekingAlpha at 2018-05-16 07:38:26:000
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
via: SeekingAlpha at 2018-05-16 07:38:26:000
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come… read more...
Alder Biopharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-05-10 15:07:23:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with their 2018 Q1 earnings Read more … read more...
Alder Biopharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-05-10 15:07:23:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with their 2018 Q1 earnings Read more … read more...
Alder Biopharmaceuticals' (ALDR) CEO Paul Cleveland on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-08 23:32:03:000
Alder Biopharmaceuticals (ALDR) Q1 2018 Earnings Conference Call May 08, 2018, 05:00 PM ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Paul Cleveland - Interim President, CEO & Director Roger Cady - VP of Neurolog… read more...
Alder Biopharmaceuticals' (ALDR) CEO Paul Cleveland on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-08 23:32:03:000
Alder Biopharmaceuticals (ALDR) Q1 2018 Earnings Conference Call May 08, 2018, 05:00 PM ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Paul Cleveland - Interim President, CEO & Director Roger Cady - VP of Neurolog… read more...
Allergan Hits Another Home Run For 2nd Migraine Study
via: SeekingAlpha at 2018-04-30 04:22:10:000
Recently, Allergan ( AGN ) announced positive results from its second phase 3 study treating patients with acute migraine. The company used its drug ubrogepant to treat these patients. This is highly positive, because now it has all it needs to file an NDA to the FDA by 2019. That's why I be… read more...
Allergan Hits Another Home Run For 2nd Migraine Study
via: SeekingAlpha at 2018-04-30 04:22:10:000
Recently, Allergan ( AGN ) announced positive results from its second phase 3 study treating patients with acute migraine. The company used its drug ubrogepant to treat these patients. This is highly positive, because now it has all it needs to file an NDA to the FDA by 2019. That's why I be… read more...
Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results
via: SeekingAlpha at 2018-04-25 08:00:00:000
Analysis focus: Alder Biopharmaceuticals In mid-2017, despite seeing success in PROMISE 1, a phase 3 trial assessing Alder Biopharmaceuticals' (ALDR) eptinezumab targeting episodic migraine, the stock plummetted sharply. Investors were apparently not happy with the way the drug barely manage… read more...
Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results
via: SeekingAlpha at 2018-04-25 08:00:00:000
Analysis focus: Alder Biopharmaceuticals In mid-2017, despite seeing success in PROMISE 1, a phase 3 trial assessing Alder Biopharmaceuticals' (ALDR) eptinezumab targeting episodic migraine, the stock plummetted sharply. Investors were apparently not happy with the way the drug barely manage… read more...
Alder's eptinezumab shows treatment benefit in late-stage migraine study
via: SeekingAlpha at 2018-04-24 09:54:10:000
Results from a Phase 3 clinical trial, PROMISE 1, assessing Alder BioPharmaceuticals' ( ALDR +0.4% ) long-acting eptinezumab for the prevention of migraine showed a significant treatment effect. The data are being presented at the American Academy of Neurology Annual Meeting in Los Ange… read more...
Alder's eptinezumab shows treatment benefit in late-stage migraine study
via: SeekingAlpha at 2018-04-24 09:54:10:000
Results from a Phase 3 clinical trial, PROMISE 1, assessing Alder BioPharmaceuticals' ( ALDR +0.4% ) long-acting eptinezumab for the prevention of migraine showed a significant treatment effect. The data are being presented at the American Academy of Neurology Annual Meeting in Los Ange… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-24 08:38:39:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Outperform rating and $37 (368% upside) price target at Evercore ISI. Shares up 5% premarket. More news on: Aeglea BioTherapeutics, Alder Biopharmaceuticals Inc., Homology Medicines, Healthcare stocks news, Stocks on the mov… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-24 08:38:39:000
Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Outperform rating and $37 (368% upside) price target at Evercore ISI. Shares up 5% premarket. More news on: Aeglea BioTherapeutics, Alder Biopharmaceuticals Inc., Homology Medicines, Healthcare stocks news, Stocks on the mov… read more...
Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices
via: SeekingAlpha at 2018-04-21 09:30:08:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings for companies listed in the S&P 500 Index are up 26% from a year ago f… read more...
Biohaven Seems Attractive, But A Closer Look Puts It On The Back Burner
via: SeekingAlpha at 2018-03-27 21:22:18:000
Biohaven Pharmaceuticals ( BHVN ) on Monday reported its phase 3 data using its drug rimegepant (BHV-3000). The trial met on both co-primary endpoints of the study , but the stock dipped as low as 33% during the trading day. The good news is that it closed only slightly lower by 7.27% to … read more...
Positive late-stage results for Biohaven's rimegepant fails to lift shares, down 29% premarket
via: SeekingAlpha at 2018-03-26 08:02:43:000
Biohaven Pharmaceutical Holding Company (NYSE: BHVN ) slumps 29% premarket despite reporting successful results from two Phase 3 clinical trials assessing rimegepant for the acute treatment of migraine. More news on: Biohaven Pharmaceutical Holding Company Ltd., Novartis AG, … read more...
Alder Biopharmaceuticals Makes A Comeback
via: SeekingAlpha at 2018-02-02 12:23:09:000
After seeing a sharp pullback in the second half of 2017, Alder Biopharmaceuticals ( ALDR ) has made a strong comeback in 2018. The stock posted gains of more than 23% in the month of January. With the company on track for a BLA submission for its lead product candidate, the momentum could con… read more...
Alder Biopharmaceuticals Makes A Comeback
via: SeekingAlpha at 2018-02-02 12:23:09:000
After seeing a sharp pullback in the second half of 2017, Alder Biopharmaceuticals ( ALDR ) has made a strong comeback in 2018. The stock posted gains of more than 23% in the month of January. With the company on track for a BLA submission for its lead product candidate, the momentum could con… read more...
Alder Biopharmaceuticals Makes A Comeback
via: SeekingAlpha at 2018-02-02 12:23:09:000
After seeing a sharp pullback in the second half of 2017, Alder Biopharmaceuticals ( ALDR ) has made a strong comeback in 2018. The stock posted gains of more than 23% in the month of January. With the company on track for a BLA submission for its lead product candidate, the momentum could con… read more...
Alder Biopharmaceuticals Makes A Comeback
via: SeekingAlpha at 2018-02-02 12:23:09:000
After seeing a sharp pullback in the second half of 2017, Alder Biopharmaceuticals ( ALDR ) has made a strong comeback in 2018. The stock posted gains of more than 23% in the month of January. With the company on track for a BLA submission for its lead product candidate, the momentum could con… read more...
Biotech Forum Daily Digest For January 31st
via: SeekingAlpha at 2018-01-31 09:55:37:000
I know how men in exile feed on dreams of hope . Aeschylus The rally in the biotech sector continued on Monday as Sanofi ( SNY ) made its second acquisition with a substantial premium over the past week. Tuesday brought some profit taking into focus, which seemed logi… read more...
Biotech Forum Daily Digest For January 31st
via: SeekingAlpha at 2018-01-31 09:55:37:000
I know how men in exile feed on dreams of hope . Aeschylus The rally in the biotech sector continued on Monday as Sanofi ( SNY ) made its second acquisition with a substantial premium over the past week. Tuesday brought some profit taking into focus, which seemed logi… read more...
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
via: SeekingAlpha at 2018-01-31 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
via: SeekingAlpha at 2018-01-31 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Alder prices upsized convertible debt offering
via: SeekingAlpha at 2018-01-30 07:01:40:000
Alder BioPharmaceuticals (NASDAQ: ALDR ) prices its $250M (from $200M) offering of 2.50% convertible senior notes due 2025 at par. Underwriters have a 30-day option to purchase up to an additional $37.5M of the notes. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, … read more...
Alder prices upsized convertible debt offering
via: SeekingAlpha at 2018-01-30 07:01:40:000
Alder BioPharmaceuticals (NASDAQ: ALDR ) prices its $250M (from $200M) offering of 2.50% convertible senior notes due 2025 at par. Underwriters have a 30-day option to purchase up to an additional $37.5M of the notes. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, … read more...
Alder prices upsized convertible debt offering
via: SeekingAlpha at 2018-01-30 07:01:40:000
Alder BioPharmaceuticals (NASDAQ: ALDR ) prices its $250M (from $200M) offering of 2.50% convertible senior notes due 2025 at par. Underwriters have a 30-day option to purchase up to an additional $37.5M of the notes. More news on: Alder Biopharmaceuticals Inc., Healthcare stocks news, … read more...
Aradigm, The Final Countdown - Or: Was The 'Negative' Vote A Red Herring?
via: SeekingAlpha at 2018-01-17 14:33:57:000
I, like others, felt that frequency of exacerbations was the more important endpoint. And I think that was met. -- Randy Hawkins, Meeting of the Antimicrobial Drugs Advisory Committee, January 11, 2018 As I said, I wanted to vote in support of approval, but I recognize that… read more...
Cramer reveals the biggest winners and losers from the JP Morgan Healthcare Conference
via: CNBC at 2018-01-16 18:24:00:000
No summary available. read more...
Alder Biopharmaceuticals - Modeling The Risk/Reward
via: SeekingAlpha at 2018-01-16 10:43:58:000
I wanted to take an impartial look at Alder Biopharmaceuticals (NASDAQ: ALDR ) and see if, at the current price of $17.85, and a market of $1.21 Billion, it makes sense to take a risk on the stock. Some would say investing in an early stage biotech stock is akin to gambling. I dont ne… read more...
Game Plan For The Week - Cramer's Mad Money (1/12/18)
via: SeekingAlpha at 2018-01-15 07:39:53:000
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 12. The market is roaring and all the 401(k) money is coming in. Even Facebook's (FB) decline was not enough to derail the market. On the other hand, good earnings from JPMorgan (JPM) set a … read more...
Cramer Remix: Tuesday's the day to buy Facebook
via: CNBC at 2018-01-12 19:00:00:000
No summary available. read more...
Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM
via: SeekingAlpha at 2018-01-11 03:13:18:000
Analysis of top Seeking Alpha coverage: Roche Today we will focus on Roche ( OTCQX:RHHBY ), which is one of our favorite companies in the large cap biopharma space. The Swiss drugmaker had a solid 2017, gaining more than 10%. While this is below the performance of the IBB for 2017 (up 21… read more...
Alder Bio (ALDR) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-01-10 13:13:18:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with this Read more … read more...
Alder Bio (ALDR) Updates On Promise 2 Top-Line Data Results - Slideshow
via: SeekingAlpha at 2018-01-09 13:28:21:000
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with this Read more … read more...
Midday Gainers / Losers
via: SeekingAlpha at 2018-01-09 12:42:09:000
Gainers: PTIE +143% . DFFN +39% . KODK +31% . KEN +27% . CGG +24% . ITUS +21% . ALDR +20% . MMAC +19% . GBT +18% . ABAX +17% . More news on: Pain Therapeutics, Diffusion Pharmaceuticals Inc., Eastman Kodak Co., Stocks on the move, Read more … read more...
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
via: SeekingAlpha at 2018-01-09 11:02:20:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|